Literature DB >> 19143751

Effects of pravastatin on the function of dendritic cells in patients with coronary heart disease.

Xiang Li1, Cheng Liu, Jian Cui, Min Dong, Cheng-Hai Peng, Qing-Song Li, Jia-Li Cheng, Shu-Lin Jiang, Ye Tian.   

Abstract

The aim of the study was to investigate the functional profile of dendritic cells in patients with coronary heart disease and the effects of pravastatin on this. Forty-eight patients with coronary heart disease were divided into three groups: 16 treated with pravastatin 10 mg/day, 16 treated with pravastatin 20 mg/day and 16 not treated with pravastatin. Dendritic cells from 48 patients with coronary heart disease (before and 4 weeks after the treatment) and 16 healthy individuals were derived from peripheral blood. CD86 of dendritic cells was assessed by flow cytometry. Immunostimulatory capacity of dendritic cells was measured by mixed lymphocyte reaction. The levels of cytokines in the medium of mixed lymphocyte reaction were analysed. Blood lipids and high-sensitivity C-reactive protein were measured. Compared to normal group, more CD86+ dendritic cells were expressed in coronary heart disease and greater immunostimulatory capacity of dendritic cells in coronary heart disease was demonstrated. T lymphocytes in coronary heart disease in mixed lymphocyte reaction secreted higher levels of pro-inflammation cytokines and lower levels of anti-inflammation cytokines. CD86 expression significantly correlated with C-reactive protein, but did not correlate with low-density lipoprotein cholesterol. Both dosages of pravastatin markedly inhibited the function of dendritic cells and lowered C-reactive protein, which is independent of plasma cholesterol lowering. The anti-inflammatory effect of pravastatin showed no obvious difference between the two dosage groups. In conclusion, dendritic cells were activated in coronary heart disease and dendritic cell-mediated immune mechanisms may be involved in the pathogenesis of coronary heart disease. Pravastatin can inhibit dendritic cell activation, which is independent of plasma cholesterol lowering. Pravastatin in different doses showed no apparent differences in the inhibition of dendritic cell functions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19143751     DOI: 10.1111/j.1742-7843.2008.00340.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  3 in total

1.  Effects of simvastatin on the function of dendritic cells in patients with rheumatic arthritis.

Authors:  Yuhong Liu; Shasha Wang; Lingxun Shen; Yulan Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

Review 2.  Update on statin-mediated anti-inflammatory activities in atherosclerosis.

Authors:  Fabrizio Montecucco; François Mach
Journal:  Semin Immunopathol       Date:  2009-05-05       Impact factor: 9.623

3.  Pravastatin provides antioxidant activity and protection of erythrocytes loaded Primaquine.

Authors:  Fars Alanazi
Journal:  Int J Med Sci       Date:  2010-10-28       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.